Moore Capital Management’s BioNTech BNTX Stock Holding History

Moore Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-22,943	Closed	-$3.91M	–	701
2022 Q1	$3.91M	Buy	+22,943	New	+$3.86M	0.1%	257

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Moore Capital Management's BNTX Position: Q2 2022 in Review

Moore Capital Management sold out of BioNTech (BNTX) in Q2 2022, closing a stake of 22,943 shares — an estimated $3.91M sold.

Moore Capital Management first reported a position in BNTX in Q1 2022 and held it in 1 quarter. The position peaked at $3.91M in Q1 2022. 293 funds tracked by Wall St. Rank hold BNTX as of Q2 2022.

Moore Capital Management reported no remaining BioNTech position as of Q2 2022 after selling out during the quarter.
Moore Capital Management sold 22,943 BioNTech shares in Q2 2022, an estimated $3.91M.
Moore Capital Management first reported a position in BioNTech in Q1 2022 and held it in 1 quarter.
Moore Capital Management's BioNTech position peaked at $3.91M in Q1 2022.
293 funds tracked by Wall St. Rank held BioNTech as of Q2 2022.

Based on Moore Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.